OBSOLETE: Unclassified spondylometaphyseal dysplasia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:163678
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Unclassified spondylometaphyseal dysplasia is a term that was previously used to describe a group of rare bone disorders that affect the spine (spondylo-) and the growing ends of long bones called metaphyses. This condition has been marked as 'obsolete' in medical classification systems, meaning that as genetic knowledge has advanced, cases once grouped under this label have been reclassified into more specific types of spondylometaphyseal dysplasia or related skeletal disorders. Spondylometaphyseal dysplasias as a group cause problems with bone growth and development, typically leading to short stature, abnormal curvature of the spine, and irregularities in the shape of the long bones in the arms and legs. Patients may also experience joint pain, limited range of motion, and waddling gait. Because this is an obsolete classification, if you or your child has been given this diagnosis, it is important to seek updated genetic evaluation. Modern genetic testing can often identify the specific subtype, which helps guide treatment decisions and gives a clearer picture of what to expect. Treatment is generally supportive and may include orthopedic interventions, physical therapy, and pain management. There is currently no cure for spondylometaphyseal dysplasias, but proper management can significantly improve quality of life.

Key symptoms:

Short statureAbnormal curvature of the spineBowed legs or knock kneesJoint stiffness or limited range of motionWaddling walkBack painIrregularly shaped bones on X-rayFlattened spinal bones (platyspondyly)Widened or irregular growth plates in long bonesDifficulty with physical activitiesHip pain or hip joint problemsDelayed growth in childhood

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Unclassified spondylometaphyseal dysplasia.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Unclassified spondylometaphyseal dysplasia at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Unclassified spondylometaphyseal dysplasia community →

No specialists are currently listed for OBSOLETE: Unclassified spondylometaphyseal dysplasia.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Unclassified spondylometaphyseal dysplasia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Unclassified spondylometaphyseal dysplasiaForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Unclassified spondylometaphyseal dysplasia.

Start the conversation →

Latest news about OBSOLETE: Unclassified spondylometaphyseal dysplasia

No recent news articles for OBSOLETE: Unclassified spondylometaphyseal dysplasia.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has my condition been reclassified into a specific subtype of spondylometaphyseal dysplasia?,Should I have updated genetic testing to get a more precise diagnosis?,What kind of bone or joint problems should I watch for as I grow older?,Are there any activities I should avoid to protect my joints and spine?,What therapies or treatments can help manage pain and improve mobility?,Is there a risk of spinal cord compression, and what warning signs should I look for?,Are there any clinical trials or research studies I might be eligible for?

Common questions about OBSOLETE: Unclassified spondylometaphyseal dysplasia

What is OBSOLETE: Unclassified spondylometaphyseal dysplasia?

Unclassified spondylometaphyseal dysplasia is a term that was previously used to describe a group of rare bone disorders that affect the spine (spondylo-) and the growing ends of long bones called metaphyses. This condition has been marked as 'obsolete' in medical classification systems, meaning that as genetic knowledge has advanced, cases once grouped under this label have been reclassified into more specific types of spondylometaphyseal dysplasia or related skeletal disorders. Spondylometaphyseal dysplasias as a group cause problems with bone growth and development, typically leading to sho

At what age does OBSOLETE: Unclassified spondylometaphyseal dysplasia typically begin?

Typical onset of OBSOLETE: Unclassified spondylometaphyseal dysplasia is childhood. Age of onset can vary across affected individuals.